Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$93.00 USD
+2.27 (2.50%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $93.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Blueprint Medicines Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 711 | 945 | 477 | 872 | 484 |
Receivables | 43 | 37 | 37 | 25 | 23 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 21 | 30 | 22 | 9 | 0 |
Other Current Assets | 33 | 35 | 18 | 22 | 10 |
Total Current Assets | 808 | 1,047 | 554 | 928 | 517 |
Net Property & Equipment | 42 | 33 | 31 | 34 | 38 |
Investments & Advances | 84 | 161 | 558 | 678 | 64 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 41 | 27 | 20 | 11 | 15 |
Total Assets | 1,049 | 1,350 | 1,252 | 1,718 | 708 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 3 | 8 | 4 | 5 |
Current Portion Long-Term Debt | 30 | 17 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 7 |
Accrued Expenses | 128 | 131 | 122 | 106 | 89 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 40 | 22 | 12 | 13 | 6 |
Total Current Liabilities | 215 | 183 | 150 | 131 | 106 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 14 | 25 | 29 | 40 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 209 | 122 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 409 | 423 | 3 | 7 | 8 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 919 | 835 | 281 | 248 | 243 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,474 | 2,358 | 2,250 | 2,107 | 1,412 |
Retained Earnings | -2,340 | -1,833 | -1,275 | -631 | -945 |
Other Equity | -4 | -10 | -4 | -5 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 131 | 515 | 971 | 1,470 | 464 |
Total Liabilities & Shareholder's Equity | 1,049 | 1,350 | 1,252 | 1,718 | 708 |
Total Common Equity | 131 | 515 | 971 | 1,470 | 464 |
Shares Outstanding | 60.70 | 59.80 | 58.80 | 55.70 | 49.20 |
Book Value Per Share | 2.15 | 8.61 | 16.51 | 26.39 | 9.44 |
Fiscal Year End for Blueprint Medicines Corporation falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 711 | 713 | 723 | 822 |
Receivables | NA | 43 | 41 | 38 | 31 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 21 | 16 | 17 | 18 |
Other Current Assets | NA | 33 | 37 | 33 | 29 |
Total Current Assets | NA | 808 | 808 | 811 | 900 |
Net Property & Equipment | NA | 42 | 41 | 37 | 34 |
Investments & Advances | NA | 84 | 142 | 142 | 167 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 41 | 39 | 39 | 40 |
Total Assets | NA | 1,049 | 1,105 | 1,106 | 1,220 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 7 | 7 | 11 |
Current Portion Long-Term Debt | NA | 30 | 30 | 18 | 17 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 128 | 110 | 101 | 109 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 40 | 38 | 32 | 25 |
Total Current Liabilities | NA | 215 | 197 | 169 | 173 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 5 | 5 | 5 | 5 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 209 | 208 | 122 | 122 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 408 | 412 | 416 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 919 | 903 | 795 | 806 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 2,474 | 2,434 | 2,411 | 2,381 |
Retained Earnings | NA | -2,340 | -2,229 | -2,095 | -1,963 |
Other Equity | NA | -4 | -3 | -4 | -5 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 131 | 203 | 311 | 414 |
Total Liabilities & Shareholder's Equity | NA | 1,049 | 1,105 | 1,106 | 1,220 |
Total Common Equity | 0 | 131 | 203 | 311 | 414 |
Shares Outstanding | 61.20 | 60.70 | 60.70 | 60.60 | 60.40 |
Book Value Per Share | 0.00 | 2.15 | 3.34 | 5.13 | 6.86 |